CYP2D6 and Tamoxifen: Awaiting the Denouement Reply

被引：0
|
作者：
Rae, James M. [1 ]
机构：
[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 34期
关键词：
PHARMACOGENETICS; METABOLITE;
D O I：
10.1200/JCO.2011.39.0971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4590 / 4591
页数：3
相关论文
共 50 条
  • [31] CYP2D6 tamoxifen: Pharmacogenetics in early breast cancer
    Brauch H.
    Schroth W.
    Der Gynäkologe, 2010, 43 (7): : 579 - 585
  • [32] CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance
    Michaela J. Higgins
    Vered Stearns
    Current Oncology Reports, 2010, 12 : 7 - 15
  • [33] Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
    Zembutsu, Hitoshi
    Sasa, Mitsunori
    Kiyotani, Kazuma
    Mushiroda, Taisei
    Nakamura, Yusuke
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (02) : 185 - 193
  • [34] Concurrent tamoxifen and CYP2D6 inhibitor SSRIs not risky
    Reactions Weekly, 2016, 1622 (1) : 5 - 5
  • [35] Understanding CYP2D6 and Its Role in Tamoxifen Metabolism
    Smith, Edith Caroline
    ONCOLOGY NURSING FORUM, 2013, 40 (06) : 547 - 548
  • [36] CYP2D6 and tamoxifen: pharmacogenetic reinvention of an established drug?
    von Ahsen, Nicolas
    Binder, Claudia
    Brockmoeller, Juergen
    Oellerich, Michael
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2009, 33 (05): : 293 - 302
  • [37] CYP2D6 pharmacogenetics stratifies tamoxifen treatment outcome
    Schroth, W.
    Goetz, M. R.
    Hamann, U.
    Fasching, P. A.
    Schmidt, M.
    Winter, S.
    Fritz, P.
    Suman, V. J.
    Ames, M. M.
    Simon, W.
    Ulmer, H.
    Bolaender, J.
    Strick, R.
    Beckmann, M. W.
    Koelbl, H.
    Black, J.
    Avila, R.
    Weinshilboum, R.
    Ingle, J. N.
    Eichelbaum, M.
    Schwab, M.
    Brauch, H.
    BREAST, 2009, 18 : S34 - S34
  • [38] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [39] Evaluating the impact of missenses mutations in CYP2D6*7 and CYP2D6*14A: does it compromise tamoxifen metabolism?
    Borba, Maria A. C. S. M.
    Melo-Neto, Renato P.
    Leitao, Glauber M.
    Castelletti, Carlos H. M.
    Lima-Filho, Jose L.
    Martins, Danyelly B. G.
    PHARMACOGENOMICS, 2016, 17 (06) : 561 - 570
  • [40] CYP2D6 and Ockham's razor - Reply
    Lim, Hyeong-Seok
    Ro, Jungsil
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 687 - 687
12345